A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.

Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma / Pellegrini, Cinzia; Broccoli, Alessandro; Pulsoni, Alessandro; Rigacci, Luigi; Patti, Caterina; Gini, Guido; Mannina, Donato; Tani, Monica; Rusconi, Chiara; Romano, Alessandra; Vanazzi, Anna; Botto, Barbara; Santoro, Armando; Hoaus, Stefan; Rigolin, Gian Matteo; Musto, Pellegrino; Mazza, Patrizio; Molica, Stefano; Corradini, Paolo; Fama, Angelo; Gaudio, Francesco; Merli, Michele; Ronconi, Fioravante; Gritti, Giuseppe; Vallisa, Daniele; Tosi, Patrizia; Liberati, Anna Marina; Pinto, Antonello; Pavone, Vincenzo; Gherlinzoni, Filippo; Bianchi, Maria Paola; Volpetti, Stefano; Trentin, Livio; Goldaniga, Maria Cecilia; Bonfichi, Maurizio; Renzo, Amalia De; Schiavotto, Corrado; Spina, Michele; Carella, Angelo Michele; Stefoni, Vittorio; Argnani, Lisa; Zinzani, Pier Luigi. - In: ONCOTARGET. - ISSN 1949-2553. - 8:53(2017), pp. 91703-91710. [10.18632/oncotarget.18114]

Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

Pellegrini, Cinzia;Pulsoni, Alessandro;Romano, Alessandra;Fama, Angelo;Gaudio, Francesco;Bianchi, Maria Paola;
2017

Abstract

A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.
2017
Brentuximab vedotin; Hodgkin's lymphoma; Long-term response; Real life; Stem cell transplantation; Oncology
01 Pubblicazione su rivista::01a Articolo in rivista
Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma / Pellegrini, Cinzia; Broccoli, Alessandro; Pulsoni, Alessandro; Rigacci, Luigi; Patti, Caterina; Gini, Guido; Mannina, Donato; Tani, Monica; Rusconi, Chiara; Romano, Alessandra; Vanazzi, Anna; Botto, Barbara; Santoro, Armando; Hoaus, Stefan; Rigolin, Gian Matteo; Musto, Pellegrino; Mazza, Patrizio; Molica, Stefano; Corradini, Paolo; Fama, Angelo; Gaudio, Francesco; Merli, Michele; Ronconi, Fioravante; Gritti, Giuseppe; Vallisa, Daniele; Tosi, Patrizia; Liberati, Anna Marina; Pinto, Antonello; Pavone, Vincenzo; Gherlinzoni, Filippo; Bianchi, Maria Paola; Volpetti, Stefano; Trentin, Livio; Goldaniga, Maria Cecilia; Bonfichi, Maurizio; Renzo, Amalia De; Schiavotto, Corrado; Spina, Michele; Carella, Angelo Michele; Stefoni, Vittorio; Argnani, Lisa; Zinzani, Pier Luigi. - In: ONCOTARGET. - ISSN 1949-2553. - 8:53(2017), pp. 91703-91710. [10.18632/oncotarget.18114]
File allegati a questo prodotto
File Dimensione Formato  
Pellegrini_Italian_2017.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 780.86 kB
Formato Adobe PDF
780.86 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1114244
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact